{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Erlandson KM"],"funding":["KOWA Pharmaceuticals","National Institute of Allergy and Infectious Diseases","NIDDK NIH HHS","NIA NIH HHS","NIAID NIH HHS","Statistical and Data Management Center","NHLBI NIH HHS","Leadership and Operations Center","Clinical Coordinating Center","National Institutes of Health","Gilead Sciences","ViiV Healthcare"],"pagination":["1154-1163"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9525090"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["75(7)"],"pubmed_abstract":["<h4>Background</h4>We sought to explore multinational differences in functional status by global burden of disease (GBD) regions in the REPRIEVE cohort.<h4>Methods</h4>REPRIEVE is a prospective, double-blind, randomized, placebo-controlled, multicenter, phase III primary cardiovascular prevention study of pitavastatin calcium vs placebo among people with human immunodeficiency virus (HIV, PWH) ages 40-75 on antiretroviral therapy (ART). GBD super regions were defined using World Health Organization classifications. Participants were categorized by impairment on the Duke Activity Status Instrument (DASI: none, some, moderate, severe). Logistic regression models examined risk factors and GBD regions associated with functional impairment. The association between functional impairment and card"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk."],"pmcid":["PMC9525090"],"funding_grant_id":["R01 AG054366","UM1 AI069456","UM1 AI106701","UM1 AI068634","UM1 AI068636","U01 HL123339","U01 HL123336","U01HL123336","P30DK 040561","U01HL123339","P30 DK040561","UM1 AI069452","UM1 AI069399","UM1 AI069432","UM1 AI069453"],"pubmed_authors":["Fitch KV","Aberg JA","Overton ET","Bares S","Bloomfield GS","Fichtenbaum CJ","Mave V","Grinspoon SK","Fulda ES","Santana-Bagur JL","Douglas PS","Castro JG","Erlandson KM","Brown TT","McCallum SA","Ribaudo HJ","Supparatpinyo K","Moran LE","Ponatshego PL","Zanni MV","Schechter M"],"additional_accession":[]},"is_claimable":false,"name":"Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk.","description":"<h4>Background</h4>We sought to explore multinational differences in functional status by global burden of disease (GBD) regions in the REPRIEVE cohort.<h4>Methods</h4>REPRIEVE is a prospective, double-blind, randomized, placebo-controlled, multicenter, phase III primary cardiovascular prevention study of pitavastatin calcium vs placebo among people with human immunodeficiency virus (HIV, PWH) ages 40-75 on antiretroviral therapy (ART). GBD super regions were defined using World Health Organization classifications. Participants were categorized by impairment on the Duke Activity Status Instrument (DASI: none, some, moderate, severe). Logistic regression models examined risk factors and GBD regions associated with functional impairment. The association between functional impairment and card","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T13:28:50.953Z","creation":"2025-04-19T13:28:50.953Z"},"accession":"S-EPMC9525090","cross_references":{"pubmed":["35165682"],"doi":["10.1093/cid/ciac098"]}}